Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector Assay Kit for Non-Small Cell Lung Cancer Patients - Seite 2

About Target Selector Molecular Assay Kits
Target Selector molecular assay kits are marketed for research-use-only (RUO) in the U.S. and CE-IVD in the European Union and other CE Mark geographies, offering industry-leading sensitivity for the detection of mutations/variants of interest in both FFPE and ctDNA. Target Selector assays with Switch-Blocker technology can also provide results with smaller DNA inputs (minimum 4.6 ng) than most tissue-based assays, allowing laboratories to get results even with small amounts of tissue. These capabilities should allow laboratories to eliminate macro-dissection of tumor blocks, potentially resulting in major workflow improvements and cost savings.

Target Selector assays can be used in combination with a variety of low-cost analytical platforms including qPCR, Sanger sequencing, microarrays, and mass-spectrometry, in addition to next generation sequencing. Target Selector kits (RUO and CE-IVD) offer high content per assay, which can reduce costs by selectively amplifying multiple mutations/variants in hot-spot regions of interest in a single reaction. All Target Selector assays are quantitative.

Target Selector molecular assay kits (RUO and CE-IVD) are currently available for EGFR and BRAF mutations. Additional test kits for other oncogene mutations are planned for launch in the future. For more information on Biocept's Target Selector molecular assay kits, contact Biocept Customer Service at [phone] or [e-mail].

About Protean BioDiagnostics
Protean BioDiagnostics Inc is a disruptive biotechnology company developing and commercializing novel cancer diagnostics supporting precision oncology. Protean has created Oncology MAPS - a unique and innovative, fully integrated diagnostic system for oncologists. This easy-to-deploy system enables rapid access to precision diagnostics for underserved community-based cancer doctors and their patients wherever they practice. Oncology MAPS includes comprehensive support and access to the latest genetic, molecular and cancer blood monitoring tests as well as educational and telemedicine support.

Protean is transforming cancer practice using a big data approach which integrates digital pathology, multi-omics, and artificial intelligence. Protean also provides support for contract research, clinical trials, and novel biomarker development using its CAP-accredited, CLIA-certified laboratories and through its extensive client networks.